

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Reumuth Mary</u> (Last) (First) (Middle) <u>C/O KALA PHARMACEUTICALS, INC.</u> <u>100 BEAVER STREET, SUITE 201</u> (Street) <u>WALTHAM MA 02453</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>07/19/2017</u>	3. Issuer Name and Ticker or Trading Symbol <u>Kala Pharmaceuticals, Inc. [KALA]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Financial Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	(1)	10/02/2024	Common Stock	11,520	2.3	D	
Stock Option (right to buy)	(2)	10/02/2024	Common Stock	11,520	2.3	D	
Stock Option (right to buy)	(3)	12/04/2024	Common Stock	15,360	2.3	D	
Stock Option (right to buy)	(4)	10/02/2025	Common Stock	5,077	5.21	D	
Stock Option (right to buy)	(5)	06/17/2026	Common Stock	92,096	3.34	D	

Explanation of Responses:

- This option was granted on October 2, 2014 and vests over four years, with 25% of the shares underlying the option vested on February 3, 2015, and an additional 2.0833% of the shares underlying the option vesting at the end of each successive one-month period thereafter.
- This option was granted on October 2, 2014 and vests over four years, with to 25% of the shares underlying the option vested on August 18, 2015, and an additional 2.0833% of the shares underlying the option vesting at the end of each successive one-month period thereafter.
- This option was granted on December 4, 2014 and vests over four years, with 25% of the shares underlying the option vested on December 4, 2015 and an additional 2.0833% of the shares underlying the option vesting at the end of each successive one-month period thereafter.
- This option was granted on October 2, 2015 and vests over four years, with 25% of the shares underlying the option vested on October 2, 2016, and an additional 2.0833% of the shares underlying the option vesting at the end of each successive one-month period thereafter.
- This option was granted on June 17, 2016 and vests over four years, with 25% of the shares underlying the option vested on June 17, 2017, and an additional 2.0833% of the shares underlying the option vesting at the end of each successive one-month period thereafter.

/s/ Mary Reumuth

07/19/2017

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.